Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: Data from two randomized phase III trials

noticia |

Van Soest R.J., Templeton A.J., Vera-Badillo F.E., Mercier F., Sonpavde G., Amir E., Tombal B., Rosenthal M., Eisenberger M.A., Tannock I.F., DeWit R.

Annals of Oncology 2015 26:4 (743-749)

Background: The neutrophil-to-lymphocyte ratio (NLR), a marker of host inflammation, has been associated with poor outcome in several solid tumors. Here, we investigated associations of the derived NLR (dNLR) and duration of initial androgen deprivation therapy (ADT) with survival of men with metastatic castration-resistant prostate cancer (mCRPC) receiving first-line chemotherapy. Patients and methods: Data from the multinational randomized phase III studies VENICE and TAX327 included a total of 2230 men with mCRPC randomized to receive first-line chemotherapy, and were used as training and validation sets, respectively. Associations of dNLR and duration of initial ADT with overall survival (OS) were evaluated by multivariable Cox regression analysis in the training set stratified for performance status and treatment arm. The model was then tested in the validation set. Subsequently, we investigated the treatment effect of docetaxel on OS in subgroups according to dNLR and duration of initial ADT. Results: In the training set, both dNLR ?median (2) and duration of initial ADT <median (15 months) were associated with…(vermás)

Valorar

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...